Cadrenal Therapeutics Inc (CVKD)

$3.60 +0.43 (13.56%)
Market Cap 10.33M
Revenue (ttm) 0.00
Net Income (ttm) -13.24M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 107,100
Avg Vol 76,912
Day's Range N/A - N/A
Shares Out 2.87M
Stochastic %K 78%
Beta 1.73
Analysts Strong Sell
Price Target $27.67

Company Profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005...

Industry: Biotechnology
Sector: Healthcare
Phone: 904 300 0701
Address:
822 A1A North, Suite 306, Ponte Vedra, United States
topstockalerts
topstockalerts Jul. 3 at 8:46 PM
$CVKD this one is making a pretty compelling case
0 · Reply
Orlandotrader
Orlandotrader Jul. 3 at 12:53 AM
$CVKD Let’s see what they have. July 12 Presentation.
0 · Reply
PaidBashar
PaidBashar Jul. 2 at 4:14 PM
$CVKD hint: the executives now have salaries for a few more years while the science goes nowhere GLTA
0 · Reply
History101
History101 Jul. 2 at 3:46 PM
$CVKD nice pop
0 · Reply
History101
History101 Jul. 2 at 1:22 AM
$CVKD This aged really well, share price down 60% since Dec 17
0 · Reply
History101
History101 Jul. 2 at 1:18 AM
$CVKD June 30, 2026 direct offer, ballpark numbers: CVKD received $3MM Inv received 960k shares @ $3.12. Inv received 1,920k wrnts (2x the # shares), exerc ~ $3. OS after Dec 15, 2025 offer = 2.338MM, so shares alone (not incl wrnts) = 41% dilution. Wrnts ensure sp is capped at $3 for long time. Wrnts can be used as hedges for short positions. Sounds like an Anson deal. Dec 15, 2025 direct offer, ballpark numbers: CVKD received $1.9MM Inv received 207k shares @ $10.85 + 414k wrnts excer $10.60 Notice the nice lil pump right before the Dec 15 offer
0 · Reply
History101
History101 Jul. 1 at 7:19 PM
$CVKD wow, management decided to actually inform investors on this dilution. The last one they did there was zero announcement, i looked all day until i was able to find an obscure article about it.
0 · Reply
MarketsParadise
MarketsParadise Jul. 1 at 5:17 PM
Small caps heating up, We are seeing some big runners lately. Take a look at ticker DRCT 💎 I believe this is the next monster runner waiting to be found: DRCT 💎 • 600K share float! • AI-powered digital advertising & marketing drive. • Extremely thin chart. • Any sustained buying pressure we look for the 5$+. $VRAX $YYGH $VMAR $CVKD .15
0 · Reply
WallStreetSignals
WallStreetSignals Jul. 1 at 1:56 PM
$CVKD Latest Press Release | Cadrenal Therapeutics, Inc. (Nasdaq: #CVKD) Announces a Private Placement of Up to $8.8 Million Priced in Accordance with At-The-Market Guidelines Under Nasdaq Regulations. https://www.globenewswire.com/news-release/2026/07/01/3320268/0/en/cadrenal-therapeutics-announces-up-to-8-8-million-private-placement-priced-at-the-market-under-nasdaq-rules.html #TheBullRunShow #Investing #Biotech #NASDAQ #CVKD
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 1 at 12:56 PM
$CVKD (-8.1% pre) Cadrenal Therapeutics launches up to $8.8M private placement https://ooc.bz/l/106649
0 · Reply
Latest News on CVKD
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Jun 30, 2026, 8:00 PM EDT - 3 days ago

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

Jun 24, 2026, 8:00 AM EDT - 10 days ago

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

Cadrenal Therapeutics to file for FDA RPDD for tecarfarin in Kawasaki Disease

2026-06-18T13:07:47.000Z - 16 days ago

Cadrenal Therapeutics to file for FDA RPDD for tecarfarin in Kawasaki Disease

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Jun 18, 2026, 9:00 AM EDT - 16 days ago

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Cadrenal Therapeutics to initiate CAD-1005 trial

2026-06-15T13:15:54.000Z - 19 days ago

Cadrenal Therapeutics to initiate CAD-1005 trial

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Jun 15, 2026, 8:30 AM EDT - 19 days ago

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

Jun 3, 2026, 9:00 AM EDT - 4 weeks ago

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

Cadrenal Therapeutics Transcript: Lytham Partners Spring 2026 Investor Conference

May 28, 2026, 9:30 AM EDT - 5 weeks ago

Cadrenal Therapeutics Transcript: Lytham Partners Spring 2026 Investor Conference

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

May 19, 2026, 4:30 PM EDT - 6 weeks ago

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

May 7, 2026, 8:30 AM EDT - 2 months ago

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Cadrenal Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Cadrenal Therapeutics Quarterly report: Q1 2026

Cadrenal Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Cadrenal Therapeutics Earnings release: Q1 2026

Cadrenal Therapeutics Slides: Investor presentation

May 4, 2026, 7:00 AM EDT - 2 months ago

Cadrenal Therapeutics Slides: Investor presentation

Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA

2026-04-30T13:59:21.000Z - 2 months ago

Cadrenal Therapeutics completes CAD-1005 End-of-Phase 2 meeting with FDA

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Apr 30, 2026, 8:30 AM EDT - 2 months ago

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

HIT

Cadrenal Therapeutics Registration statement: Registration filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Cadrenal Therapeutics Registration statement: Registration filing

Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders

2026-04-21T10:05:19.000Z - 2 months ago

Cadrenal Therapeutics files to sell 1.18M shares of common stock for holders

Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright

2026-04-07T15:40:11.000Z - 3 months ago

Cadrenal Therapeutics price target lowered to $13 from $32 at H.C. Wainwright

Cadrenal Therapeutics Inc trading halted, volatility trading pause

2026-04-01T19:36:49.000Z - 3 months ago

Cadrenal Therapeutics Inc trading halted, volatility trading pause

Cadrenal Therapeutics Inc trading resumes

2026-04-01T19:35:16.000Z - 3 months ago

Cadrenal Therapeutics Inc trading resumes

Cadrenal Therapeutics Annual report: Q4 2025

Mar 31, 2026, 9:00 AM EDT - 3 months ago

Cadrenal Therapeutics Annual report: Q4 2025

Cadrenal Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 9:00 AM EDT - 3 months ago

Cadrenal Therapeutics Earnings release: Q4 2025

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

Mar 31, 2026, 8:45 AM EDT - 3 months ago

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

Cadrenal Therapeutics Transcript: Life Sciences Virtual Investor Forum

Mar 12, 2026, 3:00 PM EDT - 4 months ago

Cadrenal Therapeutics Transcript: Life Sciences Virtual Investor Forum

Cadrenal Therapeutics highlights research on 12-LOX inhibition

2026-03-12T12:21:38.000Z - 4 months ago

Cadrenal Therapeutics highlights research on 12-LOX inhibition

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

Mar 12, 2026, 8:00 AM EDT - 4 months ago

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

Cadrenal Therapeutics highlights recent 12-LOX inhibitor platform expansion

2026-03-02T13:37:53.000Z - 4 months ago

Cadrenal Therapeutics highlights recent 12-LOX inhibitor platform expansion

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

Mar 2, 2026, 8:00 AM EST - 4 months ago

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion

Cadrenal Therapeutics announces Phase 2 results for CAD-1005

2026-02-24T13:39:32.000Z - 4 months ago

Cadrenal Therapeutics announces Phase 2 results for CAD-1005

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

Feb 24, 2026, 8:30 AM EST - 4 months ago

Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement

Cadrenal Therapeutics Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 15, 2026, 4:30 PM EST - 6 months ago

Cadrenal Therapeutics Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Cadrenal Therapeutics highlights VLX-1005 as potential therapeutic solution

2026-01-12T13:35:38.000Z - 6 months ago

Cadrenal Therapeutics highlights VLX-1005 as potential therapeutic solution

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

Jan 12, 2026, 8:00 AM EST - 6 months ago

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

Dec 30, 2025, 8:00 AM EST - 6 months ago

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

Dec 29, 2025, 8:00 AM EST - 6 months ago

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

Cadrenal Therapeutics Registration statement: Registration Filing

Dec 29, 2025, 7:00 AM EST - 6 months ago

Cadrenal Therapeutics Registration statement: Registration Filing

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Dec 17, 2025, 9:00 AM EST - 7 months ago

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Cadrenal's Quiet Expansion Play Is Starting to Get Loud

Dec 12, 2025, 11:00 AM EST - 7 months ago

Cadrenal's Quiet Expansion Play Is Starting to Get Loud

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

Dec 12, 2025, 9:45 AM EST - 7 months ago

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia

2025-12-11T13:25:58.000Z - 7 months ago

Cadrenal Therapeutics acquires VLX-1005 for heparin-induced thrombocytopenia

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Dec 11, 2025, 8:05 AM EST - 7 months ago

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Cadrenal Therapeutics Slides: Investor presentation

Dec 11, 2025, 7:00 AM EST - 7 months ago

Cadrenal Therapeutics Slides: Investor presentation

Cadrenal Therapeutics appoints Lee Golden to board of directors

2025-12-01T14:11:18.000Z - 7 months ago

Cadrenal Therapeutics appoints Lee Golden to board of directors

PTCT

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

Dec 1, 2025, 9:00 AM EST - 7 months ago

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

PTCT

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award

Nov 19, 2025, 8:00 AM EST - 8 months ago

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award

Cadrenal Therapeutics reports Q3 EPS ($1.31) vs ($2.18) last year

2025-11-10T14:06:44.000Z - 8 months ago

Cadrenal Therapeutics reports Q3 EPS ($1.31) vs ($2.18) last year

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 9:00 AM EST - 8 months ago

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 9:00 AM EST - 8 months ago

Cadrenal Therapeutics Earnings release: Q3 2025

Cadrenal Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 9:00 AM EST - 8 months ago

Cadrenal Therapeutics Quarterly report: Q3 2025

Cadrenal Therapeutics Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 3:30 PM EDT - 9 months ago

Cadrenal Therapeutics Transcript: Lytham Partners Fall 2025 Investor Conference

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Sep 29, 2025, 4:30 PM EDT - 9 months ago

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Cadrenal announces acquisition of assets of eXIthera Pharmaceuticals

2025-09-15T12:15:05.000Z - 10 months ago

Cadrenal announces acquisition of assets of eXIthera Pharmaceuticals

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors

Sep 15, 2025, 8:00 AM EDT - 10 months ago

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors

Cadrenal Therapeutics reports Q2 EPS ($1.87), consensus ($1.77)

2025-08-11T12:20:21.000Z - 11 months ago

Cadrenal Therapeutics reports Q2 EPS ($1.87), consensus ($1.77)

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 8:00 AM EDT - 11 months ago

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Cadrenal Therapeutics Earnings release: Q2 2025

Cadrenal Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Cadrenal Therapeutics Quarterly report: Q2 2025

Cadrenal Therapeutics announces trial plans for tecarfarin

2025-08-05T10:25:11.000Z - 11 months ago

Cadrenal Therapeutics announces trial plans for tecarfarin

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Aug 5, 2025, 6:00 AM EDT - 11 months ago

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Cadrenal Therapeutics Proxy statement: Proxy Filing

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Proxy statement: Proxy Filing

Cadrenal Therapeutics Proxy statement: Proxy Filing

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Proxy statement: Proxy Filing

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

May 15, 2025, 7:30 AM EDT - 1 year ago

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

Cadrenal Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cadrenal Therapeutics Earnings release: Q1 2025

Cadrenal Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Cadrenal Therapeutics Quarterly report: Q1 2025

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Apr 17, 2025, 9:40 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Cadrenal Therapeutics Earnings release: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Cadrenal Therapeutics Earnings release: Q4 2024

Cadrenal Therapeutics Annual report: Q4 2024

Mar 13, 2025, 9:30 AM EDT - 1 year ago

Cadrenal Therapeutics Annual report: Q4 2024

Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial

2025-03-04T13:21:36.000Z - 1 year ago

Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial

ABT

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Mar 4, 2025, 8:00 AM EST - 1 year ago

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

ABT

Cadrenal Therapeutics CMO Douglas Losordo departs, James Ferguson succeeds

2025-02-06T14:10:14.000Z - 1 year ago

Cadrenal Therapeutics CMO Douglas Losordo departs, James Ferguson succeeds

MTNB

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Feb 6, 2025, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Feb 5, 2025, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Cadrenal Therapeutics Transcript: Lytham Partners 2025 Investor Healthcare Summit

Jan 13, 2025, 10:30 AM EST - 1 year ago

Cadrenal Therapeutics Transcript: Lytham Partners 2025 Investor Healthcare Summit

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 9, 2025, 8:44 AM EST - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cadrenal Therapeutics to initiate Phase 3 clinical trial for tecarfarin in 2025

2024-12-31T13:10:18.000Z - 1 year ago

Cadrenal Therapeutics to initiate Phase 3 clinical trial for tecarfarin in 2025

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Dec 31, 2024, 8:00 AM EST - 1 year ago

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Dec 18, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Nov 19, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Cadrenal Therapeutics Registration statement: Registration Filing

Nov 14, 2024, 7:00 AM EST - 1 year ago

Cadrenal Therapeutics Registration statement: Registration Filing

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Nov 12, 2024, 9:00 AM EST - 1 year ago

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Cadrenal Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 4:00 PM EST - 1 year ago

Cadrenal Therapeutics Quarterly report: Q3 2024

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Nov 7, 2024, 9:00 AM EST - 1 year ago

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Nov 1, 2024, 8:00 PM EDT - 1 year ago

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Oct 24, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Oct 23, 2024, 9:00 AM EDT - 1 year ago

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Cadrenal Therapeutics Transcript: Lytham Partners Fall 2024 Investor Conference

Oct 1, 2024, 2:00 PM EDT - 1 year ago

Cadrenal Therapeutics Transcript: Lytham Partners Fall 2024 Investor Conference

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Sep 23, 2024, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Aug 22, 2024, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Cadrenal Therapeutics Transcript: Summer 2024 Investor Summit Virtual MicroCap Forum

Aug 20, 2024, 3:00 PM EDT - 2 years ago

Cadrenal Therapeutics Transcript: Summer 2024 Investor Summit Virtual MicroCap Forum

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Aug 20, 2024, 9:00 AM EDT - 2 years ago

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 2 years ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA ELUT EUDA GDTC GOSS GOVX IMRN

Cadrenal Therapeutics Transcript: Sidoti Micro-Cap Virtual Conference

Aug 15, 2024, 2:30 PM EDT - 2 years ago

Cadrenal Therapeutics Transcript: Sidoti Micro-Cap Virtual Conference

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Aug 14, 2024, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

topstockalerts
topstockalerts Jul. 3 at 8:46 PM
$CVKD this one is making a pretty compelling case
0 · Reply
Orlandotrader
Orlandotrader Jul. 3 at 12:53 AM
$CVKD Let’s see what they have. July 12 Presentation.
0 · Reply
PaidBashar
PaidBashar Jul. 2 at 4:14 PM
$CVKD hint: the executives now have salaries for a few more years while the science goes nowhere GLTA
0 · Reply
History101
History101 Jul. 2 at 3:46 PM
$CVKD nice pop
0 · Reply
History101
History101 Jul. 2 at 1:22 AM
$CVKD This aged really well, share price down 60% since Dec 17
0 · Reply
History101
History101 Jul. 2 at 1:18 AM
$CVKD June 30, 2026 direct offer, ballpark numbers: CVKD received $3MM Inv received 960k shares @ $3.12. Inv received 1,920k wrnts (2x the # shares), exerc ~ $3. OS after Dec 15, 2025 offer = 2.338MM, so shares alone (not incl wrnts) = 41% dilution. Wrnts ensure sp is capped at $3 for long time. Wrnts can be used as hedges for short positions. Sounds like an Anson deal. Dec 15, 2025 direct offer, ballpark numbers: CVKD received $1.9MM Inv received 207k shares @ $10.85 + 414k wrnts excer $10.60 Notice the nice lil pump right before the Dec 15 offer
0 · Reply
History101
History101 Jul. 1 at 7:19 PM
$CVKD wow, management decided to actually inform investors on this dilution. The last one they did there was zero announcement, i looked all day until i was able to find an obscure article about it.
0 · Reply
MarketsParadise
MarketsParadise Jul. 1 at 5:17 PM
Small caps heating up, We are seeing some big runners lately. Take a look at ticker DRCT 💎 I believe this is the next monster runner waiting to be found: DRCT 💎 • 600K share float! • AI-powered digital advertising & marketing drive. • Extremely thin chart. • Any sustained buying pressure we look for the 5$+. $VRAX $YYGH $VMAR $CVKD .15
0 · Reply
WallStreetSignals
WallStreetSignals Jul. 1 at 1:56 PM
$CVKD Latest Press Release | Cadrenal Therapeutics, Inc. (Nasdaq: #CVKD) Announces a Private Placement of Up to $8.8 Million Priced in Accordance with At-The-Market Guidelines Under Nasdaq Regulations. https://www.globenewswire.com/news-release/2026/07/01/3320268/0/en/cadrenal-therapeutics-announces-up-to-8-8-million-private-placement-priced-at-the-market-under-nasdaq-rules.html #TheBullRunShow #Investing #Biotech #NASDAQ #CVKD
0 · Reply
OpenOutcrier
OpenOutcrier Jul. 1 at 12:56 PM
$CVKD (-8.1% pre) Cadrenal Therapeutics launches up to $8.8M private placement https://ooc.bz/l/106649
0 · Reply
RotterdamTrade
RotterdamTrade Jul. 1 at 9:57 AM
$CVKD 3.15 for the shares ? Nice took some because fear of dillution is now gone.
0 · Reply
focafoca99
focafoca99 Jul. 1 at 4:31 AM
$CVKD initiated a private placement priced at-market under Nasdaq rules, targeting up to $8.8 million to extend cash runway into 2027.
0 · Reply
STACKD0E
STACKD0E Jul. 1 at 2:14 AM
$JEM $CVKD $BTOG ✨️
0 · Reply
VAULTF600
VAULTF600 Jun. 25 at 7:54 PM
$CVKD can it really sink further?
2 · Reply
WallStreetSignals
WallStreetSignals Jun. 24 at 5:13 PM
$CVKD #StockToWatch | $CVKD #CadrenalTherapeutics Breakthrough Moment in 2026 https://www.nasdaq.com/press-release/cadrenal-therapeutics-announces-selection-cad-1005-phase-2-study-late-breaking-oral #TheBullRunShow #AI #NASDAQ #NDAQ #wsj #nytimes #business #reuters #IHub_StockPosts #forbes #marketwatch #cnn #bet #foxnews #latimes
0 · Reply
WallStreetSignals
WallStreetSignals Jun. 24 at 5:11 PM
$CVKD: Discover the Future of HIT Treatment https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-selection-of-cad-1005-phase-2-study-5stbe42ry5n3.html #TheBullRunShow #CadrenalTherapeutics #CAD1005 #ISTH2026 #ClinicalResearch #Pharmaceuticals
0 · Reply
MikeTechnician
MikeTechnician Jun. 24 at 4:01 PM
$CVKD - Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement https://www.cadrenal.com/
0 · Reply
MikeTechnician
MikeTechnician Jun. 24 at 3:02 PM
$CVKD https://stockscan.io/stocks/CVKD
0 · Reply
WallStreetSignals
WallStreetSignals Jun. 24 at 2:06 PM
$CVKD #CVKD Cadrenal Therapeutics, Inc. Phase 2 CAD-1005 study has been chosen for a late-breaking oral presentation at the ISTH 2026 Congress. https://www.nasdaq.com/press-release/cadrenal-therapeutics-announces-selection-cad-1005-phase-2-study-late-breaking-oral #CAD1005 #ISTH2026 #ClinicalTrials #ResearchNews #InnovativeTherapeutics @followers @topfans #TheBullRunShow
0 · Reply
WallStreetSignals
WallStreetSignals Jun. 24 at 1:35 PM
$CVKD Special News | #CVKD Cadrenal Therapeutics said its CAD-1005 Phase 2 study has been chosen for a late-breaking oral presentation at the ISTH 2026 Congress. https://www.nasdaq.com/press-release/cadrenal-therapeutics-announces-selection-cad-1005-phase-2-study-late-breaking-oral #TheBullRunShow #Cadrenal #CAD1005 #ISTH2026 #ClinicalTrials #HealthcareInnovation @MikeTechnician @LadonnaKelly @SaraWelch @OnTheBalance @BioTuesdays @EfamhS
1 · Reply
MikeTechnician
MikeTechnician Jun. 24 at 12:42 PM
$CVKD Breaking News : Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress https://finance.yahoo.com/healthcare/articles/cadrenal-therapeutics-announces-selection-cad-120000124.html
0 · Reply
MikeTechnician
MikeTechnician Jun. 22 at 4:14 PM
$CVKD - announced plans to submit a Rare Pediatric Disease Designation (RPDD) request to the U.S. Food and Drug Administration (FDA) for tecarfarin as a treatment for pediatric patients with Kawasaki disease (KD) who develop coronary artery aneurysms (CAAs) and require chronic oral anticoagulation. The announcement comes ahead of the BIO International Convention, June 22–25, 2026, in San Diego, California. Cardenal's executive leadership team will highlight this rare pediatric initiative and its Phase 3-ready CAD-1005 platform during one-on-one partnering meetings with global and regional pharmaceutical companies.
0 · Reply